NodeSMARTNCT07085442
Audit of Targeted Sentinel Node Biopsy (TSNB) in Patients With Limited Nodal Disease Undergoing Primary Surgery
StatusRecruiting
PhaseNot specified
Primary completion (estimated)
At risk: Primary completion moved at least 11 months later, primary endpoint(s) modified.
See at-risk trials from University Hospitals of Derby and Burton NHS Foundation Trust
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 23 versions: 22 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary endpoint(s) modified
- Eligibility criteria shortened, about 47 words
- Study description expanded, about 3 words
- Notable Eligibility criteria shortened, about 14 words
- Primary endpoints revised (20)
- Minor Study sites: 12 to 14
- Notable Eligibility criteria expanded, about 6 words
- Notable Eligibility criteria expanded, about 13 words
- Secondary endpoints: details revised at 15 of 25 entries
- Site details revised at 1 of 12 sites
- Study description expanded, about 1 word
- Notable Primary and study completion pushed from Dec 2032 to Dec 2033
- Enrollment increased: 300 → 400 participants
- Notable Eligibility criteria expanded, about 34 wordsv17
- Notable Eligibility criteria expanded, about 25 wordsv16
- Notable Eligibility criteria expanded, about 1 word
- Study description expanded, about 2 words
- Notable Eligibility criteria expanded, about 10 words
- Study description expanded, about 10 words
- Notable Enrollment increased: 200 → 300 participantsv12
- Minor Study sites: 10 to 12v11
- Minor Study sites: 9 to 10v10
- Minor Study sites: 8 to 9v9
- Minor Study description expanded, about 23 wordsv8
- Notable Eligibility criteria expanded, about 85 words
- Study sites: 7 to 8
- Study description expanded, about 137 words
- Minor Study sites: 6 to 7v6
- Minor Study sites: 5 to 6v5
- Minor Study sites: 4 to 5v4
- Notable Primary and study completion dates: Dec 2030 to Dec 2032
- Primary endpoints: 12 to 20
- Study sites: 2 to 4
- Secondary endpoints: 15 to 25
- Minor Study sites: 1 to 2v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Patients with ≤2 nodal metastases identified on histology.
Timeframe: 12 months
Identification rate of marked node
Timeframe: 12 months
False negative rate of targeted sentinel node biopsy
Timeframe: 12 months
Arm lymphoedema
Timeframe: 12 months
Secondary (5)
Axillary recurrence
Regional (nodal) recurrence
Disease free survival
Overall survival
Local (breast or chest wall) recurrence
Arms and interventions
Patients with biopsy proven nodal metastases (cN1) and not receiving neoadjuvant chemotherapy
Patients with T1 or T2 tumours at presentation with biopsy proven nodal metastases (cN1) and with ≤2 abnormal nodes on axillary ultrasound
Procedures: Targeted Sentinel Node Biopsy (TSNB)
Sites
14 sites in 1 country